<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587635</url>
  </required_header>
  <id_info>
    <org_study_id>19.19.CLI</org_study_id>
    <nct_id>NCT04587635</nct_id>
  </id_info>
  <brief_title>Evaluation of Changes in Bowel Movement Frequency Following the Consumption of PHGG in Adults With Constipation</brief_title>
  <acronym>TYPHOON</acronym>
  <official_title>Evaluation of Changes in Bowel Movement Frequency Following the Consumption of Partially Hydrolyzed Guar Gum (PHGG) in Adults With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Changes in Bowel Movement Frequency Following the Consumption of Partially&#xD;
      Hydrolyzed Guar Gum (PHGG) in Adults with Constipation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SBM</measure>
    <time_frame>Baseline to end of treatment, up to 6 weeks.</time_frame>
    <description>Change in mean frequency of Spontaneous Bowel Movements (SBM) as measured by the daily bowel diary from baseline to Week 6 in the treatment group compared to placebo. Frequency will be defined as the mean number of SBM for the 2-week run-in period prior to V0 and the final 2-week period of the intervention period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Constipation - Functional</condition>
  <arm_group>
    <arm_group_label>PHGG fiber</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PHGG Fiber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PHGG</intervention_name>
    <description>PHGG</description>
    <arm_group_label>PHGG fiber</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Men or women aged 18-75, inclusive.&#xD;
&#xD;
          2. Self-reported symptoms of constipation for a minimum of 3 months.&#xD;
&#xD;
          3. Constipation symptoms according to the adapted Rome IV Diagnostic Questionnaire for&#xD;
             Adults for Functional Constipation (Appendix 2) administered at screening.&#xD;
&#xD;
          4. Cleveland Clinic constipation score (CCCS) of 8-20.&#xD;
&#xD;
          5. Low-moderate fiber intake (≤18g) determined by the semi-quantitative food intake&#xD;
             screener known as the Block Fiber Screener completed by site personnel.&#xD;
&#xD;
          6. Ability to understand the participant information sheet and instructions, and able to&#xD;
             provide informed consent.&#xD;
&#xD;
          7. Access to a suitable smartphone device (Android or iOS) with ability to download and&#xD;
             complete the study e-Diary daily for the duration of the trial.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Pregnant women or breastfeeding.&#xD;
&#xD;
          2. Ongoing other diagnosed gastrointestinal disease or complication (Crohn's disease,&#xD;
             Ulcerative Colitis, Coeliac disease, chronic diarrhoea).&#xD;
&#xD;
          3. Any clinically relevant abnormalities in the screening visit physical examination or&#xD;
             alarm features in the medical history such as sudden unintentional weight loss (&gt;10%&#xD;
             in 3 months), frequent rectal bleeding not caused by anal fissures or hemorrhoids,&#xD;
             recent change in bowel habit (&lt;3 months), severe abdominal pain and stool positive for&#xD;
             occult blood.&#xD;
&#xD;
          4. Prior abdominal surgery (including gastric bypass or laparoscopic banding), except&#xD;
             cholecystectomy and appendectomy.&#xD;
&#xD;
          5. Neurologic diseases such as multiple sclerosis, stroke, spinal cord injury,&#xD;
             Hirschsprung disease.&#xD;
&#xD;
          6. Chronic usage of any medication that in the opinion of the investigator would impact&#xD;
             gut motility two weeks prior to the initial administration of study product or up to a&#xD;
             minimum of 5 times the half-life of the medication if it has a long half-life.&#xD;
&#xD;
          7. Illness that may preclude the participant's ability to complete the study or that may&#xD;
             confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness,&#xD;
             severe cardiovascular disease, chronic renal failure or eating disorders) or any other&#xD;
             serious illness resulting in &gt;2 weeks inability to work in the 3 months before the&#xD;
             study start.&#xD;
&#xD;
          8. Participants with co-morbid illnesses such as cardiovascular, endocrine, renal or&#xD;
             other chronic disease likely to affect gut motility or limit normal functions (e.g.&#xD;
             reduced mobility or increased fragility).&#xD;
&#xD;
          9. Ongoing alcohol, drug, or medication abuse (anamnesis only).&#xD;
&#xD;
         10. Self-reported symptoms of pelvic organ prolapse, such as feeling of pressure or&#xD;
             fullness in the pelvic area, intra vaginal discomfort, painful intercourse and urinary&#xD;
             problems.&#xD;
&#xD;
         11. Moderate or severe active local anorectal problems such as recurrent anal fissures,&#xD;
             frequent bleeding, large prolapsing haemorrhoids.&#xD;
&#xD;
         12. Regular use of fiber (e.g. Fybogel, Lactulose) (i.e. no more than 1 standard dose)&#xD;
             over the week prior to the screening visit and no more than 6 standard doses in the&#xD;
             past 1 month prior to the screening visit.&#xD;
&#xD;
         13. Consumption of any type of yoghurts or probiotic-containing products, i.e. any&#xD;
             commercially available product specified as containing Lactobacillus, Bifidobacteria,&#xD;
             Streptococcus, Saccharomyces such as Activia, Actimel, Yakult, in the 4 weeks prior to&#xD;
             randomization (V0).&#xD;
&#xD;
         14. Participation in another study with any investigational product within 6 months of&#xD;
             screening.&#xD;
&#xD;
         15. Participation in another constipation trial in the past year.&#xD;
&#xD;
         16. Investigator believes that the participant is physically or mentally unfit to&#xD;
             participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Muckley, FRCPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altantia Food Clinical Trial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elham Pazirandeh Micol</last_name>
    <phone>+41 76 674 1360</phone>
    <email>elham.pazirandehmicol@nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trial</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Buckley</last_name>
      <phone>+353(0)214307442</phone>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

